
Sign up to save your podcasts
Or


Despite current standard care for glioblastoma being aggressive, mean survival is around 14 months. Clark Chen (director of Clinical Neuro-oncology, Beth Israel Deaconess Medical Center, Boston) argues we need a better understanding of the therapeutic concepts that have evolved over the past three decades to develop treatment, and in a JNNP article this month he lays out seven of these key ideas. Peter Warnke (JNNP associate editor) discusses them with him.
See also:
Key concepts in glioblastoma therapy http://tinyurl.com/ao8g8m3
By BMJ Group4.2
99 ratings
Despite current standard care for glioblastoma being aggressive, mean survival is around 14 months. Clark Chen (director of Clinical Neuro-oncology, Beth Israel Deaconess Medical Center, Boston) argues we need a better understanding of the therapeutic concepts that have evolved over the past three decades to develop treatment, and in a JNNP article this month he lays out seven of these key ideas. Peter Warnke (JNNP associate editor) discusses them with him.
See also:
Key concepts in glioblastoma therapy http://tinyurl.com/ao8g8m3

504 Listeners

37 Listeners

47 Listeners

299 Listeners

5 Listeners

10 Listeners

6 Listeners

3 Listeners

2 Listeners

3 Listeners

26 Listeners

40 Listeners

14 Listeners

1 Listeners

53 Listeners

0 Listeners

6 Listeners

15 Listeners

3 Listeners

26 Listeners

23 Listeners

136 Listeners

1,251 Listeners

83 Listeners

0 Listeners